# Administration practice and adherence of nusinersen in adults with 5q-spinal muscular atrophy in China: an ambispective multicenter study

**Authors:** Xiaoli Yao, Yi Dai, Wenhua Zhu, Yuying Zhao, Huifang Shang, Qiang Meng, Yaling Liu, Liqiang Yu, Daojun Hong, Juanjuan Chen, Lu Shen, Wanjin Chen, Ken Chen, Li Zhang, Maerhaba Mai, Liying Cui

PMC · DOI: 10.1186/s12883-026-04730-x · BMC Neurology · 2026-02-28

## TL;DR

This study examines how nusinersen is administered and how well patients follow the treatment schedule for spinal muscular atrophy in China.

## Contribution

The study provides real-world data on nusinersen administration and adherence in Chinese adults with 5q-spinal muscular atrophy.

## Key findings

- Nusinersen was administered with a high adherence rate of 92.8% in Chinese adults with 5q-SMA.
- Most injections were performed via interspinous lumbar puncture without sedation or ventilatory support.
- Participants with scoliosis required more imaging guidance during administration compared to those without scoliosis.

## Abstract

Due to nusinersen’s route of administration and dosing regimen, the spinal muscular atrophy (SMA) population and/or their caregivers need to travel to hospitals and work around physician’s schedules to receive treatment. Real-world studies with large sample sizes on administration practice and adherence rate of nusinersen are lacking, especially in non-United States settings. This study aimed to investigate the administration practice and adherence of nusinersen in Chinese adults with 5q-SMA.

An ambispective, multicenter registry of adults with 5q-SMA in China provided the longitudinal data for this analysis. Nusinersen was scheduled on Day 0, 14, 28, 63, and every 4 months thereafter. Adherence rate was calculated at dose level. A dose was deemed adherent if the interval between the current and preceding dose aligned with the standard dosing regimen, allowing a grace period of ± 7 days for doses 2 through 4 and ± 28 days for all subsequent doses.

A total of 177 participants receiving nusinersen with 1,329 doses were included in the study. All injections were given in inpatient setting with no ventilatory support or sedation needed. Only one injection (0.1%) was performed under general anesthesia. Almost all (n = 1,322, 99.5%) injections were given through interspinous lumbar puncture. Injections in participants with scoliosis require more imaging techniques for guiding administration compared with those in participants without scoliosis (68.3% vs. 29.1%). Ultrasound was the most commonly used guide before or during administration (674/708). The adherence rate was 92.8% (1,062/1,144). The median inter-dose intervals aligned well with dosing schedule, with 14 days for Dose 2 and 3, 35 days for Dose 4, and 120–124 days for Dose 5 to 10 as maintenance doses.

Findings characterize the patterns of nusinersen administration practice, demonstrating high real-world adherence to nusinersen administration in Chinese adults with 5q-SMA.

The registry was registered at clinicaltrials.gov (NCT05618379) on November 16th, 2022.

The online version contains supplementary material available at 10.1186/s12883-026-04730-x.

## Linked entities

- **Diseases:** spinal muscular atrophy (MONDO:0001516)

## Full-text entities

- **Diseases:** spinal muscular atrophy (MESH:D009134)
- **Chemicals:** nusinersen (MESH:C000590926)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13001292/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13001292/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC13001292/full.md

---
Source: https://tomesphere.com/paper/PMC13001292